Results 31 to 40 of about 1,690 (152)

Case report: Therapy adherence, MTTP variants, and course of atheroma in two patients with HoFH on low-dose, long-term lomitapide therapy

Frontiers in Genetics, 2023
Background: Homozygous familial hypercholesterolemia (HoFH) is a rare and devastating genetic condition characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) leading to an increased risk of premature atherosclerosis ...
Meral Kayikcioglu, Hasan Selcuk Ozkan, Burcu Yagmur, Selen Bayraktaroglu, Asli Tetik Vardarli   +4 more
doaj   +1 more source

Assessment of the global and national market for lipid modifying agents: retrospective and innovation

Сибирский научный медицинский журнал, 2023
Lipid-lowering therapy is one of the most important aspects in the treatment of patients with cardiovascular disease, which is still the leading cause of death in the adult population.
A. V. Lokhmacheva, S. G. Fominykh, L. V. Trubina, I. E. Sikhvardt   +3 more
doaj   +1 more source

Unlocking the therapeutic potential of RNA splicing in lung fibrosis: Insights from the SRSF7–PKM axis [PDF]

Acta Pharmaceutica Sinica B
Bi-Sen Ding
doaj   +2 more sources

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Atherosclerosis Plus, 2021
Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels.
Maria Giovanna Lupo, Diletta Arcidiacono, Alice Zaramella, Fabio Fimiani, Paolo Calabrò, Angelo Baldassare Cefalù, Maurizio Averna, Laura D'Erasmo, Marcello Arca, Sara De Martin, Alberto Zambon, Nicola Ferri   +11 more
doaj   +1 more source

THE IMPACT OF EVINACUMAB THERAPY ON PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM PART B OF A PHASE 3 TRIAL

American Journal of Preventive Cardiology, 2023
Therapeutic Area: ASCVD /CVD Risk Reduction Background: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels.
Albert Wiegman, Susanne Greber-Platzer, Shazia Ali, Divya Singh, M. Doortje Reijman, Eliot A Brinton, Min-Ji Charng, Shubha Srinivasan, Carissa Baker-Smith, Seth Baum, Julie Brothers, Jacob Hartz, Patrick M. Moriarty, Poulabi Banerjee, Richard T George, Robert Pordy   +15 more
doaj   +1 more source

Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia

Orphanet Journal of Rare Diseases, 2018
Background Homozygous familial hypercholesterolaemia (HoFH) is characterized by a markedly increased risk of premature cardiovascular (CV) events and cardiac death.
Dirk J. Blom, Marina Cuchel, Miranda Ager, Helen Phillips   +3 more
doaj   +1 more source

Oligogenic Familial Hypercholesterolemia Treated by Combination Therapy of Statin, Ezetimibe, PCSK9 Inhibitor, and Lomitapide. [PDF]

Intern Med
We encountered a 40-year-old man diagnosed with homozygous familial hypercholesterolemia (FH) based on clinical findings. The initial low-density lipoprotein (LDL)-cholesterol level was 393 mg/dL.
Kojima N, Tada H, Takamura M.
europepmc   +2 more sources

Xanthomas Regression in an 8-Year-Old Boy Treated With Lomitapide

JACC: Case Reports, 2019
This case reports on an 8-year-old boy with homozygous familial hypercholesterolemia with large tuberous xanthomas over his hands, elbows, buttocks, knees, and feet.
Genovefa Kolovou, MD, PhD, Aleksandros Tsoutsinos, MD, Irene Mastorakou, MD, MSc, PhD, Sophie Mavrogeni, MD, PhD, George Hatzigeorgiou, MD   +4 more
doaj   +1 more source

Lomitapide mesylate and lomitapide target ALDOA to inhibit growth and enhance gemcitabine efficacy in PDAC. [PDF]

iScience
Summary Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy with limited therapeutic options. We performed a high-throughput viability screen in PDAC cell lines and identified lomitapide mesylate and lomitapide as potent candidates.
Liu YJ, Zhao FY, Wang JM, Li BQ, Lu SY, Li C, Wang HQ.   +6 more
europepmc   +2 more sources

Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites

Molecules, 2020
With the continued loss of antimalarials to resistance, drug repositioning may have a role in maximising efficiency and accelerating the discovery of new antimalarial drugs.
Ana Carolina C. de Sousa, Keletso Maepa, Jill M. Combrinck, Timothy J. Egan   +3 more
doaj   +1 more source